Loading patent…
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsPaulo Fontoura, Hideki Garren, William H. Robinson, Lawrence Steinman, Pedro Jose Ruiz, Paul J. Utz
Estimating the term…
This invention provides a method of treating or preventing a disease in an animal associated with one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present or involved in a non-physiologic process in the animal comprising administering to the animal a self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) associated with the disease. Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) modulates an immune response to the self-protein(s), -polypeptide(s) or -peptide(s) expressed from administration of the self-vector. The invention also provides a composition comprising a polynucleotide encoding one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present non-physiologically in a treated animal useful in treating or preventing a disease associated with the self-protein(s), -polypeptide(s), or -peptide(s) present in and/or the target of a non-physiologic process in the animal.
A method of treating a disease in a subject associated with one or more self-protein(s), -polypeptide(s) or -peptide(s) present in the subject non-physiologically comprising administering to the subject a self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) associated with the disease.
A method of treating multiple sclerosis in a subject comprising administering to the subject a self-vector comprising a polynucleotide encoding a self-protein(s), -polynucleotide(s) or -peptide(s) selected from the group consisting-of myelin basic protein (MBP), proteolipid protein (PLP), myelin associated glycoprotein (MAG), cyclic nucleotide phosphodiesterase (CNPase), myelin-associated oligodendrocytic basic protein (MBOP), myelin oligodendrocyte protein (MOG), and alpha-B crystalline.
A method of preventing a disease in a subject associated with one or more self-protein(s), -polypeptide(s) or -peptide(s) present in the subject non-physiologically comprising administering to the subject a self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) associated with the disease wherein the disease is not multiple sclerosis or insulin dependent diabetes mellitus and the self-vector is not administered by particle mediated gene gun delivery to the skin.
Dependencies are inferred from the claim text.